Johnson & Johnson has recently submitted a supplemental Biologics License Application (sBLA) to the FDA, aiming to update Tremfya’s label with new evidence showcasing its ability to inhibit the progression of structural damage in adult patients with active psoriatic arthritis (PsA). The submission is rooted in data from the Phase IIIb APEX clinical trial, where Tremfya demonstrated effectiveness in reducing joint symptoms and slowing the progression of joint damage compared to a placebo in biologic-naïve patients. This marks a significant milestone as Tremfya would become the first and only IL-23 inhibitor proven to provide symptom control and inhibit joint damage progression in individuals living with active PsA. The study investigator highlighted the importance of addressing early joint damage in PsA patients, emphasizing the impact on their mobility, work, and independence. This submission underscores the need for safe and effective treatment options that address the full spectrum of the disease, offering new hope for the psoriatic community.
Read more from appliedclinicaltrialsonline.com